Last reviewed · How we verify
DISUFENTON
DISUFENTON is a disufenton drug. It is currently in Phase 3 development.
Disufenton works by binding to a specific target, but its exact mechanism of action is unknown.
Disufenton is a small molecule with the synonyms 2,4-DISULFONYL PNB, CEROVIVE, DISUFENTON DE SODIO, DISUFENTON SODIQUE, DISUFENTON SODIUM, and DISUFENTON SODIUM. It has been studied in clinical trials for various conditions including cerebral stroke, stroke, and recurrent malignant glioma, and has been tested in combination with NXY-059, OKN-007, and Temozolomide (TMZ).
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | DISUFENTON |
|---|---|
| Drug class | disufenton |
| Target | Lipoxygenase |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 3 |
Mechanism of action
Imagine your body's cells have locks on them, and disufenton is a key that fits into one of those locks. When it binds, it can either turn the lock on or off, depending on the type of lock and the key's shape. This can help control various bodily functions, but without knowing the target, it's hard to say exactly how it works.
Approved indications
Common side effects
Key clinical trials
- Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma (PHASE2)
- Study to Determine the Safety, Tolerability, and Pharmacokinetic Profile of HPN-07 and HPN-07 Plus NAC (PHASE1)
- Safety of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke (PHASE2)
- Safety and Effectiveness of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke (PHASE3)
- Safety and Effectiveness of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DISUFENTON CI brief — competitive landscape report
- DISUFENTON updates RSS · CI watch RSS
Frequently asked questions about DISUFENTON
What is DISUFENTON?
How does DISUFENTON work?
What drug class is DISUFENTON in?
What development phase is DISUFENTON in?
What does DISUFENTON target?
Related
- Drug class: All disufenton drugs
- Target: All drugs targeting Lipoxygenase
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing